Table of Contents
ISRN Nephrology
Volume 2013 (2013), Article ID 184527, 5 pages
http://dx.doi.org/10.5402/2013/184527
Clinical Study

Residual Renal Function in Hemodialysis Patients: The Role of Angiotensin-Converting Enzyme Inhibitor in Its Preservation

1Nephrology Department, Venizeleio Hospital, 71409 Heraklion, Crete, Greece
2Nephrology Department, University Hospital of Heraklion, Voutes, 71100 Heraklion, Crete, Greece
3Department of Biological Sciences, Molecular Medicine Research Center, University of Cyprus, University House “Anastasios G. Leventis,” P.O. Box 20537, 1678 Nicosia, Cyprus

Received 18 October 2012; Accepted 29 November 2012

Academic Editors: C. Escobar, C. Fourtounas, and A. Tzamaloukas

Copyright © 2013 Dimitris Xydakis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group,” Journal of the American Society of Nephrology, vol. 7, no. 2, pp. 198–207, 1996.
  2. F. Termorshuizen, F. W. Dekker, J. G. Van Manen, J. C. Korevaar, E. W. Boeschoten, and R. T. Krediet, “Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands cooperative study on the adequacy of dialysis (NECOSAD)-2,” Journal of the American Society of Nephrology, vol. 15, no. 4, pp. 1061–1070, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Shemin, A. G. Bostom, P. Laliberty, and L. D. Dworkin, “Residual renal function and mortality risk in hemodialysis patients,” American Journal of Kidney Diseases, vol. 38, no. 1, pp. 85–90, 2001. View at Google Scholar · View at Scopus
  4. A. C. Fry, D. K. Singh, S. M. Chandna, and K. Farrington, “Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration,” Blood Purification, vol. 25, no. 3, pp. 295–302, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Montini, G. Amici, S. Milan et al., “Middle molecule and small protein removal in children on peritoneal dialysis,” Kidney International, vol. 61, no. 3, pp. 1153–1159, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Y. M. Wang, M. Wang, J. Woo et al., “A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients,” Kidney International, vol. 62, no. 2, pp. 639–647, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Morduchowicz, J. Winkler, J. R. Zabludowski, and G. Boner, “Effects of residual renal function in haemodialysis patients,” International Urology and Nephrology, vol. 26, no. 1, pp. 125–131, 1994. View at Google Scholar · View at Scopus
  8. E. Erkan, M. Moritz, and F. Kaskel, “Impact of residual renal function in children on hemodialysis,” Pediatric Nephrology, vol. 16, no. 11, pp. 858–861, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. M. P. Merkus et al., “Quality of life in patients on chronic dialysis: self assessment 3 months aftes rhe start if treatmen,” American Journal of Kidney Diseases, vol. 29, no. 4, pp. 584–592, 1997. View at Publisher · View at Google Scholar
  10. J. Rottembourg, B. Issad, J. L. Gallego et al., “Evolution of residual renal function in patients undergoing maintenance haemodialysis or continuous ambulatory peritoneal dialysis,” Proceedings of the European Dialysis and Transplant Association, vol. 19, pp. 397–403, 1983. View at Google Scholar · View at Scopus
  11. E. J. Lewis, L. G. Hunsicker, R. P. Bain, and R. D. Rohde, “The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy,” The New England Journal of Medicine, vol. 329, no. 20, pp. 1456–1462, 1993. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Maschio, D. Alberti, G. Janin et al., “Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency,” The New England Journal of Medicine, vol. 334, no. 15, pp. 939–945, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. European Best Practice Guidelines for Haemodialysis, “Section I. Measurement of renal function, when to refer and when to start dialysis,” Measurement of Renal Function Nephrol Dial Transplant, vol. 17, supplement 7, pp. 7–9, 2002. View at Google Scholar
  14. J. T. McCarthy, B. M. Jenson, D. P. Squillace, and A. W. Williams, “Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers,” American Journal of Kidney Diseases, vol. 29, no. 4, pp. 576–583, 1997. View at Google Scholar · View at Scopus
  15. R. Maiorca, G. Brunori, R. Zubani et al., “Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study,” Nephrology Dialysis Transplantation, vol. 10, no. 12, pp. 2295–2305, 1995. View at Google Scholar · View at Scopus
  16. M. W. Taal and B. M. Brenner, “Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists,” Kidney International, vol. 57, no. 5, pp. 1803–1817, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. P. K. Li, K. M. Chow, T. Y. Wong et al., “Effects of an ACEi on residual renal function in patients receiving peritoneal dialysis,” Annals of Internal Medicine, vol. 139, no. 2, pp. 105–112, 2003. View at Google Scholar
  18. A. Akbari, G. Knoll, D. Ferguson, B. McCormick, A. Davis, and M. Biyani, “Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials,” Peritoneal Dialysis International, vol. 29, no. 5, pp. 554–561, 2009. View at Google Scholar · View at Scopus
  19. P. Ruggenenti, A. Perna, G. Gherardi et al., “Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria,” The Lancet, vol. 354, no. 9176, pp. 359–364, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. J. H. Bauer, G. P. Reams, J. Hewett et al., “A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy,” American Journal of Kidney Diseases, vol. 20, no. 5, pp. 443–457, 1992. View at Google Scholar · View at Scopus
  21. J. Hartmann, H. Fricke, and H. Schiffl, “Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis,” American Journal of Kidney Diseases, vol. 30, no. 3, pp. 366–373, 1997. View at Google Scholar · View at Scopus
  22. C. Caramelo, R. Alcazar, P. Gallar et al., “Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 9, no. 6, pp. 675–677, 1994. View at Google Scholar · View at Scopus
  23. P. Stenvinkel, P. Andersson, T. Wang et al., “Do ACE-inhibitors suppress tumour necrosis factor-α production in advanced chronic renal failure?” Journal of Internal Medicine, vol. 246, no. 5, pp. 503–507, 1999. View at Publisher · View at Google Scholar · View at Scopus